SEATTLE and VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the development and ...

Please provide your email address to receive an email when new articles are posted on . Postdischarge pharmacotherapy rates rose from 12.6% in 2014 to 23.9% in 2023 for ALD-related hospitalizations.

Patients treated with cytisinicline were more likely to quit e-cigarettes compared with those who received placebo. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation ...

CHICAGO — In this video, Adam Cohen, MD, spoke to Healio about the use of minimal residual disease testing to determine cessation of therapy in patients with multiple myeloma. The MRD2STOP trial, ...

Despite decades of progress in reducing the prevalence of cigarette smoking, tobacco use remains a leading cause of preventable death and disease, and a significant driver of health care costs in the ...

A large cohort study found no increased risk for major congenital malformations (MCMs) among infants with prenatal exposure to nicotine replacement therapy (NRT), varenicline, or bupropion within 90 ...

Prenatal use of smoking cessation pharmacotherapies was not linked to increased risks of major congenital malformations (MCMs) compared with smoking during the first trimester. Nicotine replacement ...